Acuvi AB (“Acuvi” or the “Company”) carries out a rights issue of shares amounting to approximately SEK 27.8 million before issue costs (the “Rights Issue”). The Company has received subscription commitments of SEK 5.1 million and declarations of intent from investors, including Handelsbanken Fonder, bringing the total to SEK 8.8 million. Additionally, the Company has secured cost-free guarantee commitments of approximately SEK 22.2 million. As a result, the Rights Issue is fully guaranteed at 100%. Furthermore, the Board of Directors intends, subject to approval at the Annual General Meeting on May 22, 2024, to resolve on a directed share issue of approximately SEK 22.3 million to ShapeQ GmbH. The Rights Issue, together with the Directed Issue, will provide the Company with a total of approximately SEK 50.1 million. The proceeds from the issuances will primarily be used to finance sales and marketing efforts for accelerated business expansion and to strengthen the Company's financial position. The subscription period for the Rights Issue runs from June 5 to June 20, 2024.
You can find Acuvi’s full press release here.
The demand for increasingly higher precision is growing in industries such as medical technology, semiconductors, and automation. Acuvi provides unique technologies and advanced systems to support this development. The Company’s customers manufacture, for example, surgical robots, semiconductor production equipment, and diagnostic systems. Acuvi has a local presence in both Europe and the United States, with its headquarters in Uppsala.
The issuances aim to strengthen Acuvi’s balance sheet and create the financial flexibility needed to capitalize on market momentum in Germany and the United States, which has been further reinforced by the recently announced letter of intent for a collaboration and royalty agreement with the German company Nanos Instruments. Over the coming year, Acuvi plans to enhance its sales and marketing efforts in both the German and U.S. markets.
The demand for increasingly higher precision is growing in industries such as medical technology, semiconductors, and automation. Acuvi provides unique technologies and advanced systems to support this development. Our customers manufacture, for example, surgical robots, semiconductor production equipment, and diagnostic systems. Acuvi has a local presence in both Europe and the United States, with its headquarters in Uppsala.The Company’s shares are traded on Nasdaq First North Growth Market.
Corpura Fondkommission is acting as the financial advisor in connection with the Rights Issue.
For more information contact:
Carl Kindal
Phone: +46(0)73-501 58 58
Email: carl.kindal@corpura.se
